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Intramuscular myxoma is a rare benign soft tissue tumor which may be mistaken for other benign and low-grade
malignant myxoid neoplasms. We present the case of a 63-year-old woman with an asymptomatic intramuscular
myxoma discovered incidentally on a whole-body F-18 fluorodeoxyglucose (FDG) positron emission tomography
(PET)/computed tomography. PET images showed a mild FDG uptake (maximum standardized uptake value, 1.78) in
the left gluteus maximus. Subsequent magnetic resonance (MR) imaging revealed a well-defined ovoid mass with
homogenous low signal intensity on T1-weighted sequences and markedly high signal intensity on T2-weighted
sequences. Contrast-enhanced MR images showed heterogeneous enhancement throughout the mass. The
diagnosis of intramuscular myxoma was confirmed on histopathology after surgical excision of the tumor. The
patient had no local recurrence at one year follow-up. Our case suggests that intramuscular myxoma should be
considered in the differential diagnosis of an oval-shaped intramuscular soft tissue mass with a mild FDG uptake.
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Intramuscular myxoma is a rare benign soft tissue tumor
of unknown origin. It usually occurs as an isolated lesion.
The coexistence of intramuscular myxoma and skeletal fi-
brous dysplasia is known as Mazabraud’s syndrome [1]. To
the best of our knowledge, F-18 fluorodeoxyglucose (FDG)
positron emission tomography (PET)/computed tomog-
raphy (CT) findings of intramuscular myxoma have been
mentioned in one prior publication [2]. Here, we describe
a case of intramuscular myxoma with a mild FDG uptake
and discuss its clinicopathologic and radiologic features.
Case presentation
A 63-year-old previously healthy woman underwent
whole body FDG PET/CT for cancer screening. FDG
PET images demonstrated an increased uptake in the left
buttock. The maximum standardized uptake value (SUV)
was 1.78. CT showed a 3.5 cm hypodense mass, with cor-
responding tracer uptake (Figure 1). Physical examin-
ation did not show any abnormality in her left buttock.
Laboratory findings were within normal limits. Subse-
quent magnetic resonance imaging (MRI) demonstrated* Correspondence: jnishio@cis.fukuoka-u.ac.jp
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distribution, and reproduction in any mediuma well-defined soft tissue mass in the left gluteus maximus.
The mass showed homogenous low signal intensity on T1-
weighted images (Figure 2A) and markedly high signal in-
tensity on T2-weighted images (Figure 2B). A thin rim of
higher signal intensity approaching that of fat was seen
around the mass on T1-weighted images. Contrast-
enhanced T1-weighted images revealed heterogenous en-
hancement throughout the mass (Figure 2C). Based on
these findings, benign and low-grade malignant myxoid
neoplasms were suspected, including intramuscular myx-
oma and myxoid liposarcoma.
An open biopsy was performed. The tumor was com-
posed of bland spindle and stellate shaped cells that were
widely separated by myxoid stroma (Figure 3). No mi-
totic figures were seen. The tumor cells were immuno-
histochemically positive for vimentin and CD34, but
negative for S-100 protein. These findings were consist-
ent with intramuscular myxoma. We then performed a
marginal excision of the tumor. Grossly, the excised
tumor showed a gelatinous cut surface with a small cyst-
like space, measuring 3.5 × 2.0 × 1.6 cm. All tissues were
examined histologically by using sections stained with
hematoxylin and eosin. No hypercellularity, hypervas-
cularity, or mitotic figures were identified. The MIB-1 la-
beling index was less than 1%. These findings confirmedtral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 FDG PET images demonstrate an increased uptake in the left buttock. Transaxial CT shows a 3.5 cm hypodense mass, with
corresponding tracer uptake (arrows).
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tive course was uneventful, and the patient is doing well
without local recurrence one year after the surgery.
Discussion
Intramuscular myxoma has a peak incidence in the
fourth to sixth decades of life with a female predomin-
ance. It typically presents as a slowly growing, painless
mass in the large muscles of the thigh, shoulder, buttock,
and upper arm [3,4]. Marginal excision is the treatment
of choice [5]. Local recurrence is rare, and there is no
risk for metastasis. Recently, GNAS1 mutations have
been identified in intramuscular myxoma with and with-
out fibrous dysplasia [6,7]. Interestingly, Willems et al.
[8] reported that GNAS1 mutation analysis can be help-
ful to distinguish intramuscular myxoma from low-grade
myxofibrosarcoma in selected cases.
The gross appearance is characteristic and the tumor
has a mucoid, gelatinous cut surface with thin fibrous
septa. Histologically, intramuscular myxoma is composedFigure 2 Magnetic resonance imaging demonstrates a well-defined so
homogenous low signal intensity on T1-weighted images (A) and markedly
images after gadolinium administration reveal heterogenous enhancementof bland spindle and stellate shaped cells in an abundant
myxoid stroma. Fluid-filled cystic spaces are seen occa-
sionally. Mitotic activity and cellular pleomorphism are
usually absent or minimal. Some intramuscular myxomas
show focal areas of hypercellularity and hypervascularity,
which may be confused with several myxoid soft tissue
sarcomas such as myxoid liposarcoma, low-grade myxofi-
brosarcoma, and low-grade fibromyxoid sarcoma [9].
Immunohistochemically, the cells stain positively for
vimentin and show variable staining for CD34 and actin.
Immunostain for S-100 protein is typically negative.
Intramuscular myxoma is shown as a homogeneous
low-attenuating mass on CT [4]. MRI reveals a well-
defined ovoid mass exhibiting low signal intensity rela-
tive to skeletal muscle on T1-weighted images and mark-
edly high signal intensity on T2-weighted images.
Contrast-enhanced CT and MRI studies demonstrate
heterogeneous internal enhancement and/or peripheral
enhancement with occasional fine internal septa. MRI
may show surrounding fat rim or cap and surroundingft tissue mass in the left gluteus maximus. The mass shows
high signal intensity on T2-weighted images (B). Axial T1-weighted
throughout the mass (C).
Figure 3 Histologic finding of intramuscular myxoma. The
tumor is composed of bland spindle and stellate shaped cells in an
abundant myxoid stroma.
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are strongly suggestive of intramuscular myxoma, but it
might be difficult to distinguish cellular/intramuscular
myxoma from myxoid liposarcoma in some cases.
FDG PET is increasingly used for the detection and
management of soft tissue tumor. In the present case, PET
revealed an increased uptake of FDG with a maximum
SUV of 1.78. Only one case of a positive FDG PET in
intramuscular myxoma has been reported so far [2]. In
that report, the maximum SUV was 1.8 and FDG activity
was predominantly located in the periphery of the lesion.
Moreover, an appearance of Mazabraud’s syndrome on
FDG PET has been described and the SUV range for the
intramuscular myxoma lesions was between 1.3 and a
maximum of 2.6 [13]. Our case and others suggest that
intramuscular myxoma has a mild FDG uptake. The
mechanism of uptake is uncertain but may reflect a vary-
ing proportion of metabolically active cells. On the other
hand, a previous FDG PET study demonstrated that the
mean SUV for myxoid liposarcoma was 2.15 [14]. Based
on these findings, FDG PET appears to be insufficient as a
screening method for differential diagnosis between intra-
muscular myxoma and pure myxoid liposarcoma.
Conclusions
We report the second case describing FDG PET/CT im-
aging of intramuscular myxoma. This tumor should be
considered in the differential diagnosis of an oval-shaped
intramuscular soft tissue mass with a mild FDG uptake.
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